Apexigen Announces Positive Interim Results From Phase 2 Trial Evaluating Its CD40 Antibody, Sotigalimab, In Combination With Doxorubicin In Patients With Liposarcoma

  • Gary Schwartz

Press/Media

Period14 Nov 2022

Media coverage

1

Media coverage

  • TitleApexigen Announces Positive Interim Results From Phase 2 Trial Evaluating Its CD40 Antibody, Sotigalimab, In Combination With Doxorubicin In Patients With Liposarcoma
    Media name/outletMENAFN -Press Releases (English)
    Country/TerritoryJordan
    Date14/11/22
    PersonsGary Schwartz
View all 1
View less